Cholinesterase Inhibitors and Opiate Antagonists in Patients with Alzheimer's Disease

Richard J. Wurtman, Kenneth L. Davis, Celeste A. Johns, Richard C. Mohs, Blaine S. Greenwald, John P. Blass, Michael J. Reding, David Drachman, Ann Mitchell, Guila Glosser, Robert Katzman, Leon J. Thal, Steven Grenell, J. E. Spar, Asenath Larue, Edward Liston, Barry Reisberg, Steven H. Ferris, Eugene Roberts

Research output: Contribution to journalLetterpeer-review

18 Scopus citations


To the Editor: Thal and Fuld1 and Davis et al.2 described some objective improvement in cognitive functions when patients with Alzheimer's disease were given oral physostigmine (March 24 issue). The former investigators also administered a low dose of lecithin (10.8 or 3.78 g per day; the reader cannot tell whether patients received 10.8 g of 35 per cent pure material or 10.8 g of lecithin in 31 g of a preparation that was 35 per cent pure), and obtained greater improvement in their subjects. I would propose that until more is known about the extent to which cholinergic brain neurons.

Original languageEnglish
Pages (from-to)555-556
Number of pages2
JournalNew England Journal of Medicine
Issue number9
StatePublished - 1 Sep 1983
Externally publishedYes


Dive into the research topics of 'Cholinesterase Inhibitors and Opiate Antagonists in Patients with Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this